Reducing the risk of venous thromboembolism following superficial endovenous treatment: A UK and Republic of Ireland consensus study.

作者信息

Dattani Nikesh, Shalhoub Joseph, Nandhra Sandip, Lane Tristan, Abu-Own Abdulsalam, Elbasty Ahmed, Jones Aled, Duncan Andrew, Garnham Andrew, Thapar Ankur, Murray Anna, Baig Anzar, Saratzis Athanasios, Sharif Atif, Huasen Bella, Dawkins Claire, Nesbitt Craig, Carradice Daniel, Morrow Darren, Bosanquet David, Kavanagh Eamon, Shaikh Faisal, Gosi Gergely, Ambler Graeme, Fulton Gregory, Singh Gurdas, Travers Hannah, Moore Hayley, Olivier James, Hitchman Louise, O'Donohoe Martin, Popplewell Matthew, Medani Mekki, Jenkins Michael, Goh Mingzheng A, Lyons Oliver, McBride Olivia, Moxey Paul, Stather Philip, Burns Phillipa, Forsythe Rachel, Sam Rachel, Brar Ranjeet, Brightwell Robert, Benson Ruth, Onida Sarah, Paravastu Sharath, Lambracos Simon, Vallabhaneni Srinivasa R, Walsh Stewart, Aktar Tasleem, Moloney Tony, Mzimba Zola, Nyamekye Isaac

机构信息

Worcestershire Acute Hospitals NHS Trust, The Vascular Surgery Unit, Worcester, Worcestershire, UK.

*The Vascular and Endovascular Research Network (VERN) collaborators.

出版信息

Phlebology. 2020 Oct;35(9):706-714. doi: 10.1177/0268355520936420. Epub 2020 Jul 1.

DOI:10.1177/0268355520936420

PMID:32611228

Abstract

OBJECTIVES

Venous thromboembolism is a potentially fatal complication of superficial endovenous treatment. Proper risk assessment and thromboprophylaxis could mitigate this hazard; however, there are currently no evidence-based or consensus guidelines. This study surveyed UK and Republic of Ireland vascular consultants to determine areas of consensus.

METHODS

A 32-item survey was sent to vascular consultants via the Vascular and Endovascular Research Network (phase 1). These results generated 10 consensus statements which were redistributed (phase 2). 'Good' and 'very good' consensus were defined as endorsement/rejection of statements by >67% and >85% of respondents, respectively.

RESULTS

Forty-two consultants completed phase 1. This generated seven statements regarding risk factors mandating peri-procedural pharmacoprophylaxis and three statements regarding specific pharmacoprophylaxis regimes. Forty-seven consultants completed phase 2. Regarding venous thromboembolism risk factors mandating pharmacoprophylaxis, 'good' and 'very good' consensus was achieved for 5/7 and 2/7 statements, respectively. Regarding specific regimens, 'very good' consensus was achieved for 3/3 statements.

CONCLUSIONS

The main findings from this study were that there was 'good' or 'very good' consensus that patients with any of the seven surveyed risk factors should be given pharmacoprophylaxis with low-molecular-weight heparin. High-risk patients should receive one to two weeks of pharmacoprophylaxis rather than a single dose.

摘要